Bright Peak Therapeutics - About the company
Bright Peak Therapeutics is a series C company based in Basel (Switzerland), founded in 2017 by Jeffrey Bode. It operates as a Developer of small molecule-based therapeutic solutions for the treatment of cancer and autoimmune disease. Bright Peak Therapeutics has raised $232M in funding from investors like Versant Ventures, RA Capital Management and Johnson & Johnson Innovation – JJDC. The company has 3413 active competitors, including 1140 funded and 786 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of small molecule-based therapeutic solutions for the treatment of cancer and autoimmune disease. The company is involved in the development of cytokines by using Enhanced Design and Combine (EDC) platform for immuno-oncology indications.
- Website
- brightpeaktx.com
- Email ID
- *****@brightpeaktx.com
Key Metrics
Founded Year
2017
Location
Basel, Switzerland
Stage
Series C
Total Funding
$232M in 3 rounds
Latest Funding Round
Investors
Ranked
331st among 3413 active competitors
Employee Count
33 as on Sep 30, 2026
Similar Companies
Sign up to download Bright Peak Therapeutics' company profile
Bright Peak Therapeutics's funding and investors
Bright Peak Therapeutics has raised a total funding of $232M over 3 rounds. Its first funding round was on Jul 28, 2020. Its latest funding round was a Series C round on May 07, 2024 for $*****. 10 investors participated in its latest round. Bright Peak Therapeutics has 11 institutional investors.
Here is the list of recent funding rounds of Bright Peak Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 07, 2024 | 4538975 | Series C | 9201397 | 9044860 | 1134568 | 5520832 |
Mar 14, 2021 | 7598071 | Series B | 4696699 | 8610719 | 7309607 | |
Jul 28, 2020 | 3602136 | Series A | 8275871 | 3636138 | 4751058 |
Access funding benchmarks and valuations. Sign up today!View details of Bright Peak Therapeutics's funding rounds and investors
Bright Peak Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Bright Peak Therapeutics is Jeffrey Bode. Sef Kurstjens is the CEO of Bright Peak Therapeutics.
Here are the details of Bright Peak Therapeutics' key team members:
- Jeffrey Bode: Co-Founder of Bright Peak Therapeutics.
View details of Bright Peak Therapeutics's Founder profiles and Board Members
Bright Peak Therapeutics' employee count trend
Bright Peak Therapeutics has 33 employees as of Sep 26. Here is Bright Peak Therapeutics's employee count trend over the years:
Uncover Bright Peak Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Bright Peak Therapeutics's Competitors and alternates
Top competitors of Bright Peak Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Bright Peak Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
331st |  Bright Peak Therapeutics 2017, Basel (Switzerland), Series C | Developer of small molecule-based therapeutic solutions for the treatment of cancer and autoimmune disease | $232M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Bright Peak Therapeutics's competitors? Click here to see the top ones
Bright Peak Therapeutics's Investments and acquisitions
Bright Peak Therapeutics has made no investments or acquisitions yet.
Reports related to Bright Peak Therapeutics
Here is the latest report on Bright Peak Therapeutics's sector:
News related to Bright Peak Therapeutics
Media has covered Bright Peak Therapeutics for 1 event in last 1 year.
•
BrightPeak launches following acquisition of firmInsider Media•Mar 26, 2026•Bright Peak Therapeutics
•
Bright Peak Therapeutics Appoints John Schmid to its Board of DirectorsFinancial Post•Apr 17, 2025•Bright Peak Therapeutics
•
Bright Peak Therapeutics Presents New Data at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Financial Post•Nov 08, 2024•Bright Peak Therapeutics
•
Bright Peak Therapeutics has filed a notice of an exempt offering of securities to raise $89,999,991.00 in New Equity Investment.intelligence360•Jun 18, 2024•Bright Peak Therapeutics
•
J&J-backed Bright Peak secures $90m to advance immunoconjugate programmePharmaceutical Technology•Jun 11, 2024•Bright Peak Therapeutics, Johnson & Johnson Innovation, Venrock, KB Investment and 7 others
•
Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical OfficerBusiness Wire•Apr 04, 2022•Sumitomo, Bright Peak Therapeutics
•
•
Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of DirectorsBusiness Wire•Jun 10, 2021•Bright Peak Therapeutics, RA Capital Management, Versant Ventures, Fidelity Investments and 4 others
•
Ajinomoto and Bright Peak partner to develop immunocytokinesBioPharma-Reporter•Apr 01, 2021•Ajinomoto, Bright Peak Therapeutics
•
Bright Peak Therapeutics Inc. and Ajinomoto Co., Inc. Enter into a Research Collaboration and License Agreement to Create Novel ImmunocytokinesGlobeNewswire•Mar 26, 2021•Bright Peak Therapeutics, Ajinomoto
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Bright Peak Therapeutics
Explore our recently published companies
- Bank of the West - East Orange based, 1973 founded, Unfunded company
- S. Middlesex FCU - Kentwood based, Unfunded company
- Muzeumluzyckie - Germany based, 2011 founded, Unfunded company
- SmartPod Technology - Bengaluru based, 2020 founded, Unfunded company
- Warbafdb - Uganda based, 2008 founded, Unfunded company
- Spksca - Schaumburg based, 1930 founded, Unfunded company
